Abstract: Objective To evaluate the efficacy and safety of anlotinib in the treatment of elderly patients with advanced non-small cell lung cancer (NSCLC) with wild-type epidermal growth factor receptor (EGFR). Methods From June 2018 to March 2019, elderly patients with advanced NSCLC with wild-type EGFR were selected as the subjects. They underwent 2 weeks of treatment with anlotinib (12 mg/d) and 1 week of withdrawal, and 3 weeks was a course of treatment. The patients' objective response rate (ORR), disease control rate (DRR), progression free survival (PFS) and adverse reaction were recorded. Results A total of 26 patients aged 66-85 years, with a median age of 74. 5 years, were enrolled in this study. Among them, 21 cases were treated with first-line, 3 cases were treated with second-line and 2 cases were treated with third-line treatment. As of October 10, 2019, the patients' ORR was 11. 54% (3/26), DRR was 76. 92% (20/26), and the median PFS was 5. 1 months. The common adverse events were hypertension, hand-foot syndrome, fatigue, hemoptysis, thyroid dysfunction. No drug-related mortality occurred. Conclusions In the treatment of elderly patients with advanced NSCLC with wild-type EGFR, anlotinib could prolong the patients' PFS, improve ORR and DCR, and the adverse reactions are controllable.

Key words: anlotinib, non-small cell lung cancer, aged